'BioCube' searches for allergy relief

August 17, 2011

Ora Inc. is expanding its internal research efforts to include the development of a nasal allergen challenge model, as well as a new Allergen BioCube (ABC) system that can be used for evaluating anti-allergy drugs administered via both ocular and nasal routes.

Andover, MA-Ora Inc. is expanding its internal research efforts to include the development of a nasal allergen challenge model as well as a new Allergen BioCube (ABC) system that can be used for evaluating anti-allergy drugs administered via both ocular and nasal routes.

The system is a chamber-based model designed to provide a highly-controlled environment in which the mechanism of action of anti-allergy agents can be studied.

“Ora has been built upon over 30 years of the highest quality standards and scientific rigor,” said Stuart B. Abelson, president and chief executive officer of Ora. “We have used these same high standards to develop the ABC system to reproduce the signs and symptoms of allergic rhinitis in clinical trial subjects.”

According to Abelson, the company has conducted several pilot studies and validation programs to create a highly controlled environment that minimizes variability in study endpoints.

“As we expand our ABC system capabilities, we welcome companies with new chemical entities, reformulations, and line extensions to work with us on preferred terms,” he said. “The modular design of the ABC will allow us to implement future expansion plans to multiple locations to meet industry needs while maintaining the highest levels of regulatory compliance.”

Related Content:

News